ECCO 2005

Breast Cancer: Further Support for Trastuzumab from Combined Analysis

Edward Romond
Edward Romond

Edward Romond, University of Kentucky, Lexington
More data for trastuzumab comes from a combined analysis of two large, parallel trials: NSABP B-31 and NCCTG N9831. Both looked at adding trastuzumab to doxorubicin and cyclophosphamide followed by paclitaxel.

Click here for all the interviews from ECCO 2005

Similar Interviews

  • Non-Anthracyline Regimen May Be O.K. for Patients with Early Breast Cancer taking Trastuzumab (Herceptin)
  • Dennis Slamon, UCLA School of Medicine, Los Angeles It may be reasonable to replace the anthracycline component of adjuvant chemotherapy with

  • Audio Journal of Oncology 13.8, December 2005
  • Reporting from: ECCO-13 The European Cancer Conference, Paris, October 30–November 3, 2005 In this edition: Martine Piccart gave the Paris ECCO conference her

  • Audio Journal of Oncology 14.1, February 2006
  • Reporting from: - San Antonio Breast Cancer Symposium 2005 In this edition: The targeted drug trastuzumab may be used in place of anthracyclines

    Post a comment

    Subscribe to Audio Medica Podcast